FindMyKOL
Clinical trialNCT04912323RecruitingInterventional

Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease

NCT04912323 is an interventional trial sponsored by R3 Vascular Inc.. As of 21 Nov 2026, it is recruiting participants. It studies Atherosclerotic Lesion, Lower Extremity Claudication and 2 more conditions. The registry lists an enrollment of 30 participants at 7 sites in 3 countries. The registry lists a start date of 17 Aug 2021 and a primary completion date of 31 Dec 2026.

SponsorR3 Vascular Inc.Enrollment30Atherosclerotic LesionLower Extremity ClaudicationLower Extremity IschemiaPeripheral Arterial Disease
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04912323
FieldValue
Registry IDNCT04912323
StatusRecruiting
Study typeInterventional trial
Lead sponsorR3 Vascular Inc.
Enrollment30
Registered sites7
Countries3
ConditionsAtherosclerotic Lesion, Lower Extremity Claudication, Lower Extremity Ischemia and Peripheral Arterial Disease
Start17 Aug 2021
Primary completion31 Dec 2026
Study completion31 Dec 2031
Last update posted9 Apr 2024

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This first-in-human clinical feasibility study will evaluate the safety and performance of the R3 Vascular MAGNITUDE® Bioresorbable Drug-Eluting Scaffold and Delivery System in patients undergoing treatment for peripheral arterial disease severe enough to have significantly reduced the blood supply to their leg. The severe reduction in blood flow causes lifestyle limiting leg pain for these patients, and may lead to amputation of the affected limb due to the loss of tissue in the leg or foot from ulcers or gangrene. The investigational device being studied in this trial is intended to restore blood flow to the affected limb, providing symptomatic relief to the patient and reducing the risk of limb amputation. The scaffold is a type of vascular stent placed within the diseased artery below the knee to improve blood flow. Unlike commercially available metallic stents which are permanently placed within the artery, the MAGNITUDE® Bioresorbable scaffold is made of a polymer material that will completely dissolve away over time, providing the support necessary to the artery while it is healing after the treatment procedure and then slowly disappearing from the artery once that support is no longer needed. The investigational scaffold has been successfully used to treat vascular blockages in the coronary arteries of the heart, but the RESOLV I study will be the first time this device has been used to improve blood flow in the arteries of the lower leg. Patients enrolled in this study may have up to three vascular blockages in their lower leg arteries treated with the MAGNITUDE® Bioresorbable scaffold, and then will be assessed over the course of the following five years to evaluate whether the investigational treatment was successful in safely alleviating their leg pain and other symptoms.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada3 sites, 2 recruiting
  • Crchum Université Montreal

    Montreal

    Gilles Soulez, MD
    Recruiting
  • Hopital Saint-Francois D'Assise

    Québec

    Active, not recruiting
  • Toronto General Hospital

    Toronto

    Kong Teng Tan, MD
    Recruiting
Italy3 sites, 3 recruiting
  • San Donato Hospital

    Arezzo

    Francesco Liistro, MD
    Recruiting
  • Maria Cecilia Hospital

    Cotignola

    Luis M Palena, MD
    Recruiting
  • Irccs Multimedica

    Milan

    Flavio Airoldi, MD
    Recruiting
Austria1 site, 1 recruiting
  • Medical University Graz

    Graz

    Marianne Brodmann, MD
    Recruiting

Sites by country

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT04912323

Each answer restates registry values shown on this page.

What is NCT04912323?

NCT04912323 is an interventional trial sponsored by R3 Vascular Inc.. It studies Atherosclerotic Lesion, Lower Extremity Claudication and 2 more conditions.

Is NCT04912323 recruiting?

As of 21 Nov 2026, it is recruiting participants. 6 of its 7 sites list their own status as recruiting.

Who leads NCT04912323?

The registry names Juan F Granada, MD (principal investigator, Cardiovascular Research Foundation (CRF)) as the overall official.

Where does NCT04912323 run?

The registry lists 7 sites in 3 countries. Most sites are in these countries: Canada (3), Italy (3) and Austria (1).

When is NCT04912323 expected to complete?

The registry lists a primary completion date of 31 Dec 2026 and a study completion date of 31 Dec 2031. The sponsor last updated the record on 9 Apr 2024.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.